Study identifier:NIS-CRS-DUM-2010/2
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An epidemiological study to evaluate standard daily practice in managing patients with arterial hypertension and to evaluate patients’ quality of life
hypertension
-
No
-
All
300
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
This study is aimed to evaluate response rate of the antihypertensive treatment with a calcium antagonist in real life practice, to evaluate patients' quality of life and to collect the following Serbia-specific epidemiology data on hypertension: demographic data, patents characteristics, and patients' management/treatment.
Location
Location
Belgrade, Serbia
Location
Cacak, Serbia
Location
Kragujevac, Serbia
Location
Nis, Serbia
Location
Niska Banja, Serbia
Location
Pancevo, Serbia
Location
Sabac, Serbia
Location
Sremska Kamenica, Serbia
Arms | Assigned Interventions |
---|---|
1 Subject population with essential arterial hypertension currently receiving treatment with a calcium antagonist | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.